SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nabriva Therapeutics plc (NBRV) .
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($1.00, 29.6%).
- Analyst consensus target $1.00 (-29.6% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 20/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
17/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NBRV
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.11
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-21.32
Book Value / Share$0.00
Revenue / Share$13.30
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$1.00 (-29.6%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$130.92 |
$0.00 |
$15.48M |
- |
| 2014 |
$-149.52 |
$0.00 |
$-16.27M |
- |
| 2015 |
$-1,200.00 |
$84K |
$-31.39M |
-37365.5% |
| 2016 |
$-638.90 |
$0.00 |
$-54.89M |
- |
| 2017 |
$-623.15 |
$0.00 |
$-74.36M |
- |
| 2018 |
$-564.91 |
$6.5M |
$-114.78M |
-1765.8% |
| 2019 |
$-278.75 |
$7.75M |
$-82.76M |
-1068.2% |
| 2020 |
$-135.23 |
$2.86M |
$-69.48M |
-2426.1% |
| 2021 |
$-28.52 |
$27.22M |
$-49.45M |
-181.7% |
| 2022 |
$-21.32 |
$35.67M |
$-57.19M |
-160.3% |
